TGFB2 and prostate cancer: In thyroid [12], gastric [16,17] and prostate cancer [15], overexpression of miR-618 reduces the PI3K/Akt signaling pathway, inhibits TGF-β or negatively regulates the transcriptional level of TGF-β2.